Display Settings:

Format

Send to:

Choose Destination
Arch Otolaryngol Head Neck Surg. 2010 May;136(5):447-52. doi: 10.1001/archoto.2010.59.

Use of botulinum toxin type A for chronic cough: a neuropathic model.

Author information

  • 1Department of Otolaryngology-Head & Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA. chumw@evms.edu

Abstract

OBJECTIVE:

To review the experience and outcomes of a novel use of botulinum toxin type A (BtxA) in the treatment of chronic cough.

DESIGN:

Retrospective case series.

SETTING:

Academic referral center.

PATIENTS:

A total of 438 patients were diagnosed as having laryngeal spasm and chronic cough, and 6 were documented as having chronic cough treated with BtxA injections. Two patients were excluded from the study because of a history of tracheostomy or concurrent laryngeal and voice dysfunction.

INTERVENTION:

Electromyography-guided BtxA injections of the thyroarytenoid muscles.

MAIN OUTCOME MEASURES:

Patient demographics (age and sex), voice-related quality-of-life scores, postprocedure complications, number of BtxA units used, number and length of treatments, and voice outcomes are reviewed.

RESULTS:

Three of the 4 patients (75%) were women, and the mean patient age was 55.6 years (range, 38-64 years). All patients had significant relief of cough after BtxA injection, with complete resolution after a median of 7 injections (range, 4-16), using a mean dose of 4.0 U (range, 1.0-10.0 U) per treatment session for a mean duration of 25.7 months (range, 7.2-42.9 months).

CONCLUSIONS:

To our knowledge, this is the first reported series in the literature of the use of BtxA in the treatment of chronic cough in adults. In this small case series, we report a neuropathic model for chronic cough caused by neuroplastic changes and laryngeal hyperactivity as an explanation for the effectiveness of BtxA treatment. Further research and long-term follow-up are warranted, but BtxA is effective in directly decreasing laryngeal hypertonicity and possibly reducing neurogenic inflammation and neuropeptide-mediated cough. Botulinum toxin type A can be considered for the treatment of chronic cough refractory to other medical therapies.

PMID:
20479373
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk